Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKBA Akebia Therapeutics	$3.04 +5.4%	$2.23	$0.80 ▼ $3.14	$797.10M	0.88	3.82 million shs	3.94 million shs
FULC Fulcrum Therapeutics	$7.29 +5.7%	$4.24	$2.32 ▼ $10.13	$396.75M	2.29	967,680 shs	277,275 shs
PRLD Prelude Therapeutics	$0.86 -0.7%	$0.81	$0.61 ▼ $6.80	$48.78M	1.3	274,995 shs	23,538 shs
URGN UroGen Pharma	$3.95 -2.6%	$9.56	$3.42 ▼ $20.70	$181.43M	0.66	685,891 shs	576,801 shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKBA Akebia Therapeutics	-1.37%	+2.49%	+18.52%	+57.38%	+169.16%
FULC Fulcrum Therapeutics	+8.66%	+10.40%	+93.28%	+104.75%	-10.85%
PRLD Prelude Therapeutics	+8.80%	-4.82%	-1.87%	+16.78%	-76.55%
URGN UroGen Pharma	+3.05%	-2.88%	-64.03%	-56.40%	-70.24%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AKBA Akebia Therapeutics	4.033 of 5 stars	4.6	1.0	4.0	2.6	0.0	0.6
FULC Fulcrum Therapeutics	0.5382 of 5 stars	1.2	1.0	0.0	2.7	2.5	0.0
PRLD Prelude Therapeutics	3.523 of 5 stars	3.2	4.0	0.0	3.0	5.0	0.6
URGN UroGen Pharma	3.9622 of 5 stars	4.4	1.0	4.5	1.7	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKBA Akebia Therapeutics	3.20	Buy	$6.63	118.29% Upside
FULC Fulcrum Therapeutics	2.50	Moderate Buy	$5.83	-19.98% Downside
PRLD Prelude Therapeutics	2.33	Hold	$4.00	362.96% Upside
URGN UroGen Pharma	2.88	Moderate Buy	$27.43	595.27% Upside

Current Analyst Ratings Breakdown

Latest AKBA, PRLD, FULC, and URGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/29/2025	FULC Fulcrum Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$9.00
5/23/2025	FULC Fulcrum Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
5/23/2025	FULC Fulcrum Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$4.00 ➝ $12.00
5/23/2025	URGN UroGen Pharma	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $15.00
5/22/2025	URGN UroGen Pharma	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$16.00 ➝ $3.00
5/22/2025	URGN UroGen Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
5/15/2025	FULC Fulcrum Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$10.00
5/13/2025	URGN UroGen Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$55.00 ➝ $55.00
5/8/2025	URGN UroGen Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00 ➝ $25.00
5/5/2025	PRLD Prelude Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/29/2025	PRLD Prelude Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$4.00 ➝ $4.00

(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKBA Akebia Therapeutics	$184.91M	4.31	N/A	N/A	($0.16) per share	-18.97
FULC Fulcrum Therapeutics	$80M	4.92	N/A	N/A	$3.80 per share	1.92
PRLD Prelude Therapeutics	$7M	6.97	N/A	N/A	$4.32 per share	0.20
URGN UroGen Pharma	$91.87M	1.98	N/A	N/A	($2.78) per share	-1.42

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKBA Akebia Therapeutics	-$51.92M	-$0.21	N/A	N/A	N/A	-27.07%	N/A	-20.57%	8/14/2025 (Estimated)
FULC Fulcrum Therapeutics	-$97.33M	-$0.07	N/A	N/A	N/A	N/A	-7.31%	-6.74%	7/30/2025 (Estimated)
PRLD Prelude Therapeutics	-$121.83M	-$1.69	N/A	N/A	N/A	N/A	-66.89%	-55.59%	8/11/2025 (Estimated)
URGN UroGen Pharma	-$102.24M	-$3.18	N/A	N/A	N/A	-129.11%	N/A	-47.94%	8/12/2025 (Estimated)

Latest AKBA, PRLD, FULC, and URGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	URGN UroGen Pharma	-$0.83	-$0.92	-$0.09	-$0.92	$22.71 million	$20.25 million
5/8/2025	Q1 2025	AKBA Akebia Therapeutics	-$0.03	$0.03	+$0.06	$0.03	$44.88 million	$57.34 million
5/6/2025	Q1 2025	PRLD Prelude Therapeutics	-$0.47	-$0.42	+$0.05	-$0.42	N/A	N/A
5/1/2025	Q1 2025	FULC Fulcrum Therapeutics	-$0.29	-$0.28	+$0.01	-$0.28	N/A	N/A
3/13/2025	Q4 2024	AKBA Akebia Therapeutics	-$0.05	-$0.10	-$0.05	-$0.10	$37.36 million	$46.50 million
3/10/2025	Q4 2024	PRLD Prelude Therapeutics	-$0.49	-$0.38	+$0.11	-$0.38	N/A	$4.00 million
3/10/2025	Q4 2024	URGN UroGen Pharma	-$0.69	-$0.80	-$0.11	-$0.80	$25.25 million	$24.57 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKBA Akebia Therapeutics	N/A	N/A	N/A	N/A	N/A
FULC Fulcrum Therapeutics	N/A	N/A	N/A	N/A	N/A
PRLD Prelude Therapeutics	N/A	N/A	N/A	N/A	N/A
URGN UroGen Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKBA Akebia Therapeutics	N/A	1.52	1.21
FULC Fulcrum Therapeutics	N/A	18.44	18.44
PRLD Prelude Therapeutics	N/A	7.04	7.04
URGN UroGen Pharma	4.77	9.00	8.77

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKBA Akebia Therapeutics	33.92%
FULC Fulcrum Therapeutics	89.83%
PRLD Prelude Therapeutics	79.72%
URGN UroGen Pharma	91.29%

Insider Ownership

Company	Insider Ownership
AKBA Akebia Therapeutics	3.00%
FULC Fulcrum Therapeutics	7.00%
PRLD Prelude Therapeutics	63.90%
URGN UroGen Pharma	5.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKBA Akebia Therapeutics	430	262.64 million	209.24 million	Optionable
FULC Fulcrum Therapeutics	100	53.98 million	51.73 million	Optionable
PRLD Prelude Therapeutics	120	56.46 million	20.47 million	Optionable
URGN UroGen Pharma	200	46.11 million	22.26 million	Optionable

AKBA, PRLD, FULC, and URGN Headlines

Recent News About These Companies

Lost Money on UroGen Pharma Ltd. (URGN)? Contact Levi & Korsinsky About Fraud Investigation

May 29 at 10:20 AM | accessnewswire.com

UroGen Pharma Ltd. (URGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

May 29 at 10:00 AM | accessnewswire.com

Toronto Dominion Bank Takes Position in UroGen Pharma Ltd. (NASDAQ:URGN)

May 29 at 4:57 AM | marketbeat.com

Levi & Korsinsky Investigating Whether UroGen Pharma Ltd. (URGN) Misled Investors - Securities Law Violations Possible

May 28 at 10:25 AM | accessnewswire.com

Bronstein, Gewirtz & Grossman, LLC Is Investigating UroGen Pharma Ltd. (URGN) And Encourages Investors to Connect

May 28 at 10:00 AM | accessnewswire.com

Did UroGen Pharma Ltd. (URGN) Mislead Investors?

May 28 at 9:15 AM | accessnewswire.com

UroGen Pharma Ltd. (NASDAQ:URGN) Stock Position Decreased by Millennium Management LLC

May 28 at 3:43 AM | marketbeat.com

UroGen Pharma Ltd.

May 28 at 12:43 AM | marketwatch.com

UroGen Pharma to Present at TD Cowen: 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA

May 27 at 7:42 PM | finance.yahoo.com

Investigation Alert: UroGen Pharma Ltd. (URGN) Under Scrutiny - Contact Levi & Korsinsky for Details

May 27 at 3:30 PM | accessnewswire.com

UroGen Pharma Ltd. (URGN) Shares Crash Again Amid FDA's ODAC Vote Against UGN-102, Company Facing Investor Scrutiny – Hagens Berman

May 27 at 3:14 PM | globenewswire.com

Did You Suffer Losses in UroGen Pharma Ltd. (URGN)? Contact Levi & Korsinsky About Securities Fraud Claims

May 27 at 12:00 PM | accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN

May 27 at 11:50 AM | accessnewswire.com

Lost Money on UroGen Pharma Ltd. (URGN)? Contact Levi & Korsinsky to Protect Your Rights

May 27 at 10:15 AM | accessnewswire.com

Bronstein, Gewirtz & Grossman, LLC Encourages UroGen Pharma Ltd. (URGN) Stockholders to Inquire about Securities Investigation

May 27 at 10:00 AM | accessnewswire.com

Q2 EPS Estimates for UroGen Pharma Raised by HC Wainwright

May 27 at 1:18 AM | marketbeat.com

ATTENTION UroGen Pharma Ltd. (URGN) Investors: Possible Fraud - Contact Levi & Korsinsky Today

May 26 at 12:01 PM | accessnewswire.com

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against UroGen Pharma Ltd. (URGN) and Encourages Investors to Learn More About the Investigation

May 26 at 10:00 AM | accessnewswire.com

UroGen Pharma (NASDAQ:URGN) Price Target Cut to $15.00 by Analysts at Guggenheim

May 26 at 1:59 AM | americanbankingnews.com

UroGen Pharma Stock Receives Downgrade As Analyst Cites FDA Panel Setback For Key Bladder Cancer Drug

May 25, 2025 | benzinga.com

Guggenheim Cuts UroGen Pharma (NASDAQ:URGN) Price Target to $15.00

May 25, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKBA, PRLD, FULC, and URGN Company Descriptions

Akebia Therapeutics NASDAQ:AKBA

$3.04 +0.16 (+5.38%)

As of 11:56 AM Eastern

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Fulcrum Therapeutics NASDAQ:FULC

$7.29 +0.39 (+5.65%)

As of 11:55 AM Eastern

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Prelude Therapeutics NASDAQ:PRLD

$0.86 -0.01 (-0.69%)

As of 11:51 AM Eastern

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

UroGen Pharma NASDAQ:URGN

$3.94 -0.11 (-2.59%)

As of 11:55 AM Eastern

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time